Clinical Trial Update: A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study comparing selumetinib alone to selumetinib plus vinblastine in patients with recurrent or progressive low-g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Low Grade
• Glioma Who
• Low-grade Glioma

Drugs mentioned

• Koselugo (selumetinib) (selumetinib)
• Vinblastine (vinblastine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma | Phase 3 | Status: ACTIVE_NOT_RECRUITING